secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001193125-25-179958
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics prices $120M upsized public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Priced upsized $120M offering: 33.29M shares at $3.00/share and 6.71M pre-funded warrants at $2.9999 each.
- Net proceeds estimated at $112.5M (base), up to $129.5M if underwriters' 30-day option for 6M additional shares is exercised.
- Proceeds to fund commercial readiness, R&D of product candidates, and general corporate purposes.
- Cash and equivalents expected to fund operations into 2028.
- Jefferies, Piper Sandler, and Guggenheim Securities are joint bookrunners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000119312525179958/0001193125-25-179958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000119312525179958/d153873d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-179958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer